Drug intelligence / Profile preview

Vidatacro

Development stage: Unknown
Lead developer: Evervital Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

Vidatacro is a branded generic formulation of tacrolimus, an immunosuppressant developed and marketed by Evervital Lifesciences. It is approved for the prevention of organ rejection in patients receiving liver, kidney, or heart transplants. Vidatacro works by binding to the intracellular protein FKBP-12, forming a complex that inhibits calcineurin, a calcium-dependent phosphatase. This inhibition suppresses T-lymphocyte activation and reduces cytokine gene expression, thereby preventing the recipient's immune system from attacking the transplanted organ.

Brand names: Vidatacro
Other names: tacrolimus

Targets

FKBP1ACN (Calcineurin)

Beyond the preview

Go deeper on Vidatacro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vidatacro.

Explore the full profile